InvestorsHub Logo
Followers 22
Posts 4084
Boards Moderated 0
Alias Born 04/29/2016

Re: None

Wednesday, 12/21/2016 5:21:41 PM

Wednesday, December 21, 2016 5:21:41 PM

Post# of 233290
Here's my thoughts. Perhaps Nadar's meeting with Gilead is premised on a successful P3 Adjunct. From there, a little less risk going forward for Mono. However, they still have adjunct in their pocket no matter what happens with Mono. GILD is hurting right now with several set backs..i.e. Merck Patent win for one. Gild initiated a combo treatment protocol for HIV..to me..Nothing substantial, just a tweek in the number of drugs prescribed. If Adjunct data is promising, then we have a BO on our hands. This is why R/S Has been off the table..BO straight as share structure stands.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News